Search
Cancer Paid Clinical Trials in Massachusetts
A listing of 533 Cancer clinical trials in Massachusetts actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
145 - 156 of 533
The state of Massachusetts currently has 533 active clinical trials seeking participants for Cancer research studies. These trials are conducted in various cities, including Boston, Worcester, Springfield and Burlington.
Featured Trial
Lung or Breast Cancer Treatment
Recruiting
Diagnosed w/ Lung or Breast Cancer - Underwent Cancer Treatment, Take a step towards hope and healing. Enroll now in our clinical trial for an innovative breast and lung cancer treatment
Conditions:
Cancer
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Clinical Study
Recruiting
We are evaluating an investigational treatment to see if it may help people dealing with chronic cough.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Eligible participants will receive study-related medical care at no cost. You may be compensated for study-related travel and time. Health insurance is not required. If you qualify, you may receive:
Payment up to $1500, which varies by study.
Conditions:
Cough
Chronic Cough
Asthma
Allergic Asthma
Sinusitis
Featured Trial
Healthy Volunteer Trials
Recruiting
Healthy trials near you are looking for participants to help push medical research forward. Click through to learn more!
Conditions:
Healthy
Featured Trial
Healthy Volunteer Clinical Studies
Recruiting
Find a study looking for volunteers at a study site near you! Some trials offer compensation for time and travel. Click through to learn more about study opportunities.
Conditions:
Healthy
Healthy Volunteers
Featured Trial
Non-Small Cell Lung Cancer Treatment
Recruiting
A Trial to Evaluate DZD9008 as a Treatment for People with Non-Small Cell Lung Cancer with EGFR Gene Mutations
Conditions:
NSCLC
Lung Cancer
Non-Small Cell Lung Cancer
Carcinoma
Non-Small-Cell Lung
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
Recruiting
The goal of this study is to determine whether a palliative care intervention (PEACE) can improve the quality of life and experiences of participants with Lymphoma, Leukemia, or Multiple Myeloma receiving adoptive cellular therapy (ACT). After completion of an open pilot, participants will be randomly assigned into one of two study intervention groups.
The names of the study intervention groups involved in this study are:
Palliative care (PEACE) plus usual oncology care
Usual care (standard on... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts
Conditions: Hematologic Malignancy, Blood Cancer, Lymphoma, Leukemia, Multiple Myeloma
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Recruiting
The aim of this study is to provide darolutamide treatment to patients who participated in a previous study with darolutamide supported by Bayer and the treating doctor considers that the continuation of the treatment with darolutamide to be beneficial. Patients will be carried over from the previous studies and continue in this study with darolutamide treatment on the same dosage. They will also return to the study centers for doctor's visits as often as they did in the previous study.
Gender:
Male
Ages:
18 years and above
Trial Updated:
05/27/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Cancer
Study in Patients With Advanced Cancers Associated With Expression of DLL3
Recruiting
A Phase 1/2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and Pharmacokinetics of HPN328 Monotherapy and HPN328 With Atezolizumab in Patients With Advanced Cancers Associated With Expression of Delta-like Canonical Notch Ligand 3 (DLL3)
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
05/24/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma
Resistance and Aerobic Exercise for Prevention in Women With Dense Breasts (REP-D)
Recruiting
The goal of this study is to learn more about how exercise might lower the risk of developing breast cancer in women with dense breast tissue by studying changes that occur in breast tissue and blood as a result of participating in an exercise program.
The names of the study groups in this study are:
Exercise Training Group
Waitlist Control Group
Gender:
Female
Ages:
Between 18 years and 59 years
Trial Updated:
05/24/2024
Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations
Conditions: Breast Cancer, Breast Cancer Female
Colorectal Cancer Screening in Cystic Fibrosis
Recruiting
This multi-center study will compare multi-target DNA and quantitative FIT stool-based testing to colonoscopy in individuals with Cystic Fibrosis (CF) undergoing colon cancer screening with colonoscopy. The primary endpoint is detection of any adenomas, including advanced adenomas and colorectal cancer (CRC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
05/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Cystic Fibrosis, Colorectal Cancer, Adenoma
HER3-DXd in Metastatic or Unresectable Non-Small Cell Lung Cancer
Recruiting
This study is designed to evaluate safety and antitumor activity of HER3-DXd in two parts: Dose Escalation and Dose Expansion.
In Dose Escalation, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with epidermal growth factor receptor (EGFR) activating mutation after disease progression during/after EGFR tyrosine kinase inhibitor (TKI) therapy.
In Dose Expansion, HER3-DXd will be evaluated in participants with metastatic or unresectable NSCLC with EGFR activating... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/24/2024
Locations: Massachusetts General Hospital, Boston, Massachusetts +1 locations
Conditions: Non-Small Cell Lung Cancer (NSCLC)
TCF-001 TRACK (Target Rare Cancer Knowledge) Study
Recruiting
This open label, non-randomized, multi-center, pragmatic study aims to establish whether patients with rare tumors can benefit from matched molecular therapy as dictated by their next-generation sequencing (NGS) results.
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: TargetCancer Foundation, Cambridge, Massachusetts
Conditions: Rare Cancers, Cholangiocarcinoma, Cancer of Unknown Primary Site
Multisite Implementation of COMPRENDO
Recruiting
COMPRENDO (ChildhOod Malignancy Peer Research NavigatiOn) is a multi-site randomized clinical trial (RCT) that uses a Hybrid Type 1 design, to test the effects of a clinical intervention on patient-level outcomes, while exploring multilevel implementation factors that can inform real-world setting implementation. This study will test the impact of COMPRENDO, a peer-navigation intervention, vs. usual care on accrual to childhood cancer therapeutic clinical trials and parental informed consent out... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Dana Farber Cancer Institute/Boston Children's Hospital, Boston, Massachusetts
Conditions: Pediatric Cancer
A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
Recruiting
This is an open-label, dose-exploration and expansion study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of IMM-1-104 when administered as monotherapy or in combination with approved agents in participants with RAS-mutated or RAS/MAPK activated advanced or metastatic solid tumors. The dose exploration will identify the candidate recommended Phase 2 dose (RP2D) of IMM-1-104 to further explore the anti-tumor activity of IMM-1-104 as... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Dana Farber Cancer Institute, Boston, Massachusetts
Conditions: Pancreatic Adenocarcinoma, Malignant Melanoma (Cutaneous), Non-small Cell Lung Cancer (NSCLC), Advanced Solid Tumor
(Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors
Recruiting
This is a Phase 3, open-label, international, multicenter study of CGT9486 in combination with sunitinib. This is a multi-part study that will enroll approximately 426 patients. Part 1 consists of two evaluations: 1) confirming the dose of an updated formulation of CGT9486 to be used in subsequent parts in approximately 20 patients who have received at least one prior line of therapy for GIST and 2) evaluating for drug-drug interactions between CGT9486 and sunitinib in approximately 18 patients... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Dana-Farber Cancer Institute, Boston, Massachusetts
Conditions: Advanced Gastrointestinal Stromal Tumors, Metastatic Cancer
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
Recruiting
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treat... Read More
Gender:
Female
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Beverly Hospital, Beverly, Massachusetts +5 locations
Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8
An Observational Study On TheAccuracy Of Whole-Body Magnetic Resonance Imaging (Wb-Mri) ScreeningTo Predict Clinically Significant Diagnoses In General Population Subjects Interested In Proactive And Advanced General Preventive Healthcare.
Recruiting
This is a prospective, single-arm, observational study capturing data from whole-body magnetic resonance imagining (WB-MRI) from up to 100,000 male and female subjects 18 years of age or older recruited at multiple clinical sites within the United States. Study subjects must meet a set of inclusion and exclusion criteria. Potential subjects arriving at the study sites will be evaluated for enrollment. It is the Principal Investigator's (PI) responsibility to enroll only subjects who satisfy the... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/23/2024
Locations: Hercules Research Center, Watertown, Massachusetts
Conditions: Cancer, Metabolic Disease, Aneurysm, Neurologic Disorder
145 - 156 of 533